Amplifidx Inc.
- UEI
- XAAGYAVXZM43
- CAGE
- 8RJZ6
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Website
- amplifidx.com
- Founded
- 2020
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- SIC code
- 38 Instruments & Related Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| STI NG plus, a swab to answer molecular panel test for point of care diagnosis and treatment recommendation - abstract… | National Institute of Allergy and Infectious Diseases | $1,153,514 | |
| PHS 2022-1 topic 440 - cancer prevention & diagnosis technologies for low-resource settings | National Cancer Institute | $400,000 |
About Amplifidx Inc.
Amplifidx Inc. is a medical equipment manufacturing company that provides the DX 1000, a molecular point of care device for rapid medical testing. Through federal contracts and grants, the company develops diagnostic technologies aligned with federal public health initiatives.
Amplifidx has received one federal contract award: a $400,000 SBIR Phase I award from the National Cancer Institute to develop cancer prevention and diagnosis technologies for low-resource settings over two years. This definitive contract advances the NCI's goal of supporting innovative medical devices through small business research awards up to $225,000 in Phase I and up to $1.5 million in Phase II. As a woman-owned small business, Amplifidx will perform this cancer research and development work domestically.
Amplifidx has received one federal grant award as a prime recipient and has participated as a subrecipient on two other federal grants. As a prime recipient, the company received a $573,550 Project Grant from the National Institute of Allergy and Infectious Diseases to develop rapid point-of-care molecular diagnostic tests for sexually transmitted infections over two years. As a subrecipient, Amplifidx has contributed to the development of a COVID-19 rapid test under a grant from the National Institutes of Health RADx initiative and has conducted clinical studies evaluating point-of-care COVID-19 testing devices under a grant from the University of Massachusetts Medical School.
Quick answers
What is Amplifidx Inc.'s UEI?
Amplifidx Inc.'s Unique Entity ID (UEI) in SAM.gov is XAAGYAVXZM43.
What is Amplifidx Inc.'s CAGE code?
Amplifidx Inc.'s CAGE code is 8RJZ6.
What is Amplifidx Inc.'s primary NAICS code?
Amplifidx Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Is Amplifidx Inc. registered in SAM.gov?
Amplifidx Inc.'s SAM.gov registration expired on September 9, 2026.
What is Amplifidx Inc.'s most recent federal award?
Amplifidx Inc.'s most recent federal grant award is STI NG plus, a swab to answer molecular panel test for point of care diagnosis and treatment recommendation - abstract… (R43AI174562), from National Institute of Allergy and Infectious Diseases, on May 1, 2023.
On GovTribe
See Amplifidx Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors